IP Library Patent Application 10932047
Patent Application
App. No. 10/932,047

Zonisamide use in eating disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/932,047
Abstract

The present invention is directed to a method of treating overweight and/or obesity and eating disorders such as binge-eating disorders, bulimia nervosa and anorexia nervosa. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of zonisamide (1,2-benzisoxazole-3-methanesulfonamide). The present method provides a sustained and significant weight loss in an overweight subject. The method can be used in conjunction with other therapeutic agents/methods commonly used to treat overweight and eating disorders thus enhancing the therapeutic effect of reducing weight and regulating eating disorders.

Claims (13)

1 . A method for treating a binge eating disorder in a patient in need thereof comprising administering zonisamide or a pharmaceutically acceptable salt thereof in an amount of about 50 mg/day to about 1,000 mg/day.

2 . A method for treating bulimia in a patient in need thereof comprising administering zonisamide or a pharmaceutically acceptable salt thereof in an amount of about 50 mg/day to about 1,000 mg/day.

3 . A method for treating anorexia nervosa in a patient in need thereof comprising administering zonisamide or a pharmaceutically acceptable salt thereof in an amount of about 50 mg/day to about 1,000 mg/day.

4 . A method for treating an eating disorder in a patient in need thereof comprising administering a therapeutically effective amount of zonisamide or a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 , wherein the eating disorder is a binge eating disorder.

6 . The method of claim 4 , wherein the eating disorder is bulimia nervosa.

7 . The method of claim 4 , wherein the eating disorder is anorexia nervosa.

8 . The method of claim 4 , wherein the zonisamide or the pharmaceutically acceptable salt thereof is administered in an amount of about 50 to about 1000 mg/day.

9 . The method of claim 4 , wherein the zonisamide or the pharmaceutically acceptable salt thereof is administered in an amount of about 100 to about 600 mg/day.

10 . The method of claim 4 , wherein zonisamide or the pharmaceutically acceptable salt thereof is administered parenterally, topically or rectally.

11 . The method of claim 4 , wherein zonisamide or the pharmaceutically acceptable salt thereof is administered orally.

12 . The method according of claim 4 , wherein the method further comprises administering another therapeutic agent used to treat an eating disorder.

13 . The of claim 4 , further comprising administering a therapeutically effective amount of fluoxetine, topiramate or orlistat.

Assignments (2)
SECURITY AGREEMENT Recorded Mar 21, 2016
From: OREXIGEN THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 038180/0021 →
SETTLEMENT AGREEMENT Recorded Dec 18, 2006
From: ELAN CORPORATION, PLC; ELAN PHARMA INTERNATIONAL, LTD.; ELAN PHARMACEUTICALS, INC.; EISEI INC.; EISAI CO., LTD.; JENNINGS, JULIANNE E.
To: DUKE UNIVERSITY; OREXIGEN THERAPEUTICS, INC.
Reel/Frame 018676/0439 →